ClearPoint Neuro Amends Note Purchase Agreement With $20 Million Financing Linked to IRRAS Acquisition

Reuters01-05

<a href="https://laohu8.com/S/CLPT">ClearPoint Neuro</a> Amends Note Purchase Agreement With $20 Million Financing Linked to IRRAS Acquisition

ClearPoint Neuro Inc. has entered into a new agreement with CALW SA LLC, as purchaser agent, and TPC Investments III LP, an affiliate of Oberland Capital Management LLC, amending an existing Note Purchase Agreement. Under the amendment and related consent, ClearPoint Neuro will complete an internal reorganization of its Swedish subsidiary, IRRAS AB, by January 15, 2026, including transferring equity interests in IRRAS USA, Inc. to ClearPoint or its direct U.S. subsidiary. This reorganization will help IRRAS AB qualify as an "Immaterial Foreign Subsidiary" under the terms of the agreement. The amendment follows a previous arrangement for the investor to purchase $20 million in notes after ClearPoint’s acquisition of IRRAS Holdings, Inc. The material economic terms of the original Note Purchase Agreement remain unchanged.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ClearPoint Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-001581), on January 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601884345?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-05 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601884345","market":"nz","top_or_hot":-1,"title":"ClearPoint Neuro Amends Note Purchase Agreement With $20 Million Financing Linked to IRRAS Acquisition","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CLPT\">ClearPoint Neuro</a> Amends Note Purchase Agreement With $20 Million Financing Linked to IRRAS Acquisition\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ClearPoint Neuro Inc. has entered into a new agreement with CALW SA LLC, as purchaser agent, and TPC Investments III LP, an affiliate of Oberland Capital Management LLC, amending an existing Note Purchase Agreement. Under the amendment and related consent, ClearPoint Neuro will complete an internal reorganization of its Swedish subsidiary, <a href=\"https://laohu8.com/S/IRRAF\">IRRAS AB</a>, by January 15, 2026, including transferring equity interests in IRRAS USA, Inc. to ClearPoint or its direct U.S. subsidiary. This reorganization will help IRRAS AB qualify as an \"Immaterial Foreign Subsidiary\" under the terms of the agreement. The amendment follows a previous arrangement for the investor to purchase $20 million in notes after ClearPoint’s acquisition of IRRAS Holdings, Inc. The material economic terms of the original Note Purchase Agreement remain unchanged.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ClearPoint Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-001581), on January 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ClearPoint Neuro Amends Note Purchase Agreement With $20 Million Financing Linked to IRRAS Acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClearPoint Neuro Amends Note Purchase Agreement With $20 Million Financing Linked to IRRAS Acquisition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-05 21:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CLPT\">ClearPoint Neuro</a> Amends Note Purchase Agreement With $20 Million Financing Linked to IRRAS Acquisition\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ClearPoint Neuro Inc. has entered into a new agreement with CALW SA LLC, as purchaser agent, and TPC Investments III LP, an affiliate of Oberland Capital Management LLC, amending an existing Note Purchase Agreement. Under the amendment and related consent, ClearPoint Neuro will complete an internal reorganization of its Swedish subsidiary, <a href=\"https://laohu8.com/S/IRRAF\">IRRAS AB</a>, by January 15, 2026, including transferring equity interests in IRRAS USA, Inc. to ClearPoint or its direct U.S. subsidiary. This reorganization will help IRRAS AB qualify as an \"Immaterial Foreign Subsidiary\" under the terms of the agreement. The amendment follows a previous arrangement for the investor to purchase $20 million in notes after ClearPoint’s acquisition of IRRAS Holdings, Inc. The material economic terms of the original Note Purchase Agreement remain unchanged.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ClearPoint Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-001581), on January 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B1BXHZ80.USD","symbol_name":"Legg Mason ClearBridge - US Appreciation A Acc USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL2Txs8X:1","article_id":"2601884345","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601884345","pubTimestamp":1767619872,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ClearPoint Neuro Inc. has entered into a new agreement with CALW SA LLC, as purchaser agent, and TPC Investments III LP, an affiliate of Oberland Capital Management LLC, amending an existing Note Purchase Agreement. Under the amendment and related consent, ClearPoint Neuro will complete an internal reorganization of its Swedish subsidiary, IRRAS AB, by January 15, 2026, including transferring equity interests in IRRAS USA, Inc. to ClearPoint or its direct U.S. subsidiary. This reorganization will help IRRAS AB qualify as an \"Immaterial Foreign Subsidiary\" under the terms of the agreement. The amendment follows a previous arrangement for the investor to purchase $20 million in notes after ClearPoint’s acquisition of IRRAS Holdings, Inc. The material economic terms of the original Note Purchase Agreement remain unchanged.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","TRV":"旅行者财产险集团","LU0566484027.USD":"安本美国小盘成长股","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","BK4107":"财产与意外伤害保险","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","WK":"Workiva","BK4588":"碎股","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","BK4585":"ETF&股票定投概念","BK4023":"应用软件","CLPT":"ClearPoint Neuro, Inc.","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","BK4082":"医疗保健设备","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)"},"translate_title":"ClearPoint Neuro修改票据购买协议，为IRRAS收购提供2000万美元融资","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRV":0.9,"CLPT":0.9,"WK":0.9},"content_text":"ClearPoint Neuro Amends Note Purchase Agreement With $20 Million Financing Linked to IRRAS Acquisition\n    \n\n        ClearPoint Neuro Inc. has entered into a new agreement with CALW SA LLC, as purchaser agent, and TPC Investments III LP, an affiliate of Oberland Capital Management LLC, amending an existing Note Purchase Agreement. Under the amendment and related consent, ClearPoint Neuro will complete an internal reorganization of its Swedish subsidiary, IRRAS AB, by January 15, 2026, including transferring equity interests in IRRAS USA, Inc. to ClearPoint or its direct U.S. subsidiary. This reorganization will help IRRAS AB qualify as an \"Immaterial Foreign Subsidiary\" under the terms of the agreement. The amendment follows a previous arrangement for the investor to purchase $20 million in notes after ClearPoint’s acquisition of IRRAS Holdings, Inc. The material economic terms of the original Note Purchase Agreement remain unchanged.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ClearPoint Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-001581), on January 05, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601884345","isCrawlerRequest":true}